Johnson & Johnson (JNJ) Cost of Revenue (2009 - 2026)
Johnson & Johnson (JNJ) posted Cost of Revenue of $8.1 billion for Q2 2026, down 0.68% sequentially from $8.1 billion in Q1 2026, and up 5.55% YoY from $7.6 billion in Q2 2025.
Johnson & Johnson (JNJ) Cost of Revenue (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Cost of Revenue for 18 years, with the latest figure at $8.1 billion in Q2 2026.
- Quarterly Cost of Revenue rose 5.55% year-over-year to $8.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $31.4 billion (up 8.09% YoY) and the FY2025 annual result came in at $30.3 billion, up 10.14% from the prior year.
- Cost of Revenue retreated to $8.1 billion in Q2 2026 per JNJ's latest filing, from $8.1 billion in the prior quarter.
- Over five years, Cost of Revenue peaked at $8.1 billion in Q1 2026 and troughed at $2.7 billion in Q1 2023.
- A 5-year average of $6.9 billion and a median of $7.0 billion in 2024 frame the typical range for Cost of Revenue.
- The widest YoY moves for Cost of Revenue: up 152.15% in 2023, down 18.4% in 2023.
- Over 5 years, Cost of Revenue stood at $6.2 billion in 2022, then gained by 10.14% to $6.8 billion in 2023, then rose by 4.85% to $7.1 billion in 2024, then gained by 11.78% to $8.0 billion in 2025, then climbed by 1.04% to $8.1 billion in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $8.1 billion, $8.1 billion, and $8.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 8.05 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 4.29 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 4.40 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 3.71 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.52 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.81 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.58 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.09 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 3.04 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 3.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 8.05 Bn |
| Jun 28, 2026 | 8.05 Bn |
| Mar 29, 2026 | 8.11 Bn |
| Mar 29, 2026 | 8.11 Bn |
| Dec 28, 2025 | 7.97 Bn |
| Dec 28, 2025 | 7.97 Bn |
| Sep 28, 2025 | 7.30 Bn |
| Sep 28, 2025 | 7.30 Bn |
| Jun 29, 2025 | 7.63 Bn |
| Jun 29, 2025 | 7.63 Bn |
| Mar 30, 2025 | 7.36 Bn |
| Mar 30, 2025 | 7.36 Bn |
| Dec 29, 2024 | 7.13 Bn |
| Dec 29, 2024 | 7.13 Bn |
| Sep 29, 2024 | 6.96 Bn |
| Sep 29, 2024 | 6.96 Bn |
| Jun 30, 2024 | 6.87 Bn |
| Jun 30, 2024 | 6.87 Bn |
| Mar 31, 2024 | 6.51 Bn |
| Mar 31, 2024 | 6.51 Bn |